Focus on developing new delivery solutions for generic products which
with a priority on certain therapeutic segments.
Alternate drug delivery solution for generic pharmaceutical & nutraceutical products (prescription & OTC)
Step up direct marketing
Invest in R&D with a focus on entering developed markets
Add small-batch manufacturing (SBM) facilities for promoting the formulations business & supporting clients across markets with small but high-value order quantities including technology transfer from R&D.
Invest in team and processes for the development of dossiers and product registration/filings across markets.
Set-up dedicated small-batch manufacturing (SBM) facility for manufacturing pellets, tablets & granules to bring about
Chairman and Managing Director
(M. Pharm, Ph.D.)
An M. Pharm in Medicinal Chemistry and a Ph.D. in Pharmaceutics, he started his professional career in 1981 with a brief stint at IPCA Laboratories Ltd., after which he became one of the key promoters of ZIM Laboratories Ltd. which started its operations in 1990. In the subsequent years, he turned a tiny organization with fifteen employees to Central India’s premier pharmaceutical company making several novel formulation products at multi-locational manufacturing facilities and not only with a domestic footprint but also a presence in 26 countries spread over emerging markets in MENA, Latin America, CIS & Russia
Director - Finance
A chartered accountant, Zulfiquar Kamal has been associated with the company for over 25 years. He has been on the Board of Directors since 1991. With his financial acumen, refined over an experience of more than three decades, he brings to the table the financial discipline and control necessary for a growing organization like ZIM Labs. In his current role as Director – Finance, Mr. Kamal oversees the commercial operations of the company. He envisions ZIM Labs to be a financially efficient organization known for its operational efficiencies and technological process.
Director - Business Development
Mr. Niraj Dhadiwal is a pharmacy graduate with a diploma in business management and has been with the company for nearly three decades. He started his career with ZIM Labs as a production officer in 1991, rising through ranks to his current position of Director. With his keen business acumen and technical knowledge, Mr. Dhadiwal has played a key role in the export-development arm of the company. His contribution to the development of overseas business stands unmatched and a testament to his foresight and ability to tap into new markets. In his current role as Director – Business Development, Mr. Dhadiwal looks after the business development and marketing functions of the company. He envisions ZIM Labs to have a global presence with innovative and differentiated products leading to good returns for all the stakeholders.
Director - Operations
Mr. Prakash Sapkal is a Pharmacy graduate with post-graduation in Business Administration. He is associated with the Company for 24 years starting his career as Assistant Chemist. During all these years he has handled key operations in various capacities like Production Supervisor, Production Manager, and Vice President – Operations. His major contribution has been in assembling a team that has brought the vision of ZIM Labs to life.
Director - Administration
Mr. Riaz Kamal has been associated with the company since inception. His experience across these four decades extends across functions like quality control, raw material purchase, product costing and government institutional business. He has been a key player in managing the business with important contributions in the domestic institutional business, establishing and implementing policies, working processes and maintaining a disciplined and efficient workforce. In his current role as Director – Administration, Mr. Riaz looks after the government institutional business and general administration including personnel and HR departments.
Independent Director
Kavita Loya is a Senior Practicing Chartered Accountant with 20 years of experience. She is on the Board as an Independent Director. She is presently a Partner in Loya Bagri & Company, Chartered Accountants. She is a Member of Capacity Building Committee of the Western Region of ICAI, Mumbai & Women’s Empowerment Committee, Nagpur Chapter.
Independent Director
A decorated IPS officer from Maharashtra with 37 years of experience, Suprakash Chakravarty is on the Board as an Independent Director. He retired as Director General – Anti Corruption Bureau, MS.
Independent Director
Dr. Gaikwad has a Doctorate in medical sciences and has over 42 years of experience in pharmaceutical sciences. He is on the Board as an Independent Director. He retired as head of the Pharmaceutical Sciences department of Nagpur University.
Independent Director
Padmakar Joshi is a senior banking professional with more than 37 years of rich and multi-functional experience in areas of commercial banking. He is on the Board as an Independent Director. He retired as Dy. Head- Corporate & SME Credit Monitoring and Debt Restructuring, Union Bank of India.
Independent Director
With a doctorate in pharmaceutical chemistry and over 40 years of experience in academics, Dr. Parashar is on the Board of Directors as an Independent Director. He is now retired from academics.
Chairman and Managing Directo
Director - Finance
Director - Business Development
Director - Operations
Director - Administration
Senior VP – Technical Services
Mr. Vijay Fudke is a pharmacy graduate with an association of more than 20 years with ZIM. Having spent his initial years in the field of
quality control, Mr Fudke joined ZIM as a Quality Assurance (QA) Officer in 1996. He has played an instrumental role in the achievement of
various accreditations by the company, such as the EU-GMP, WHO-GMP & ISO 9001:2008. In his current role as Senior Vice President – Technical
Services, Mr Fudke is involved in providing clients with technical services like molecule selection for development, business expansion and
high-level technical query resolution. He is also involved in the Regulatory documentation for product registration and harmonization between
the customer and the internal business development teams, plant QA and R&D.
While financial growth and a strong presence in regulated markets constitute his short-term objectives, Mr Fudke’s vision is to establish
ZIM as a company with differentiated superior-quality products, processes, personnel and technology
Senior VP – Operations
Mr. Pradeep Kataria is a postgraduate in pharmacy with an association of more than 21 years with the organization. Having spent early his initial professional years in the production department of Ranbaxy Limited, Mr Kataria joined ZIM as Production Supervisor in 1995. He has been a hands-on leader of the Operations team and has been involved in successful scale-ups of pellets and taste-masking technologies developed in R&D. He has also been a meticulous administrator in developing, maintaining and managing in accordance with the high standards required for various accreditations. In his current role as Senior Vice President – Operations, Mr Kataria, with his problem-solving and administration skills, looks after day-to-day activities of the plant, including manufacturing, external audits and internal coordination amongst operational departments.
Particular | FY 2020 | FY 2021 | ||||
Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | |
Income from Operations | 652 | 621 | 681 | 624 | 654 | 818 |
Other Operating Income | 17 | 52 | 41 | 55 | 44 | 46 |
Total Income from Operations | 669 | 673 | 722 | 679 | 698 | 864 |
Operating Cost | 631 | 625 | 647 | 596 | 594 | 751 |
EBIDTA | 38 | 48 | 75 | 83 | 104 | 113 |
EBIT | 7 | 17 | 40 | 47 | 68 | 78 |
Finance costs | 32 | 32 | 32 | 30 | 29 | 27 |
Profit/(Loss) before exceptional item & tax | (25) | (15) | 8 | 17 | 39 | 51 |
Exceptional Item | - | - | - | - | - | 52 |
Profit/(Loss) before tax | (25) | (15) | 8 | 17 | 39 | (1) |
INR in Millions
Particular | FY 2018 | FY 2019 | FY 2020 | FY 2021 | |||
H1 | H2 | H1 | H2 | H1 | H2 | H1 | |
Income from Operations | 1,248 | 1,416 | 1,373 | 1,854 | 1,273 | 1,305 | 1,472 |
Other Operating Income | 29 | 41 | 37 | 53 | 69 | 96 | 90 |
Total Income from Operations | 1,277 | 1,457 | 1,410 | 1,907 | 1,342 | 1,401 | 1,562 |
Operating Cost | 1,113 | 1,247 | 1,227 | 1,645 | 1,256 | 1,243 | 1,345 |
EBIDTA | 164 | 210 | 183 | 262 | 86 | 158 | 217 |
EBIT | 117 | 159 | 128 | 205 | 24 | 87 | 146 |
Finance costs | 49 | 45 | 55 | 50 | 64 | 62 | 56 |
Profit/(Loss) before exceptional item & tax | 68 | 114 | 73 | 155 | (40) | 25 | 90 |
Exceptional Item | - | (59) | - | - | - | - | 52 |
Profit/(Loss) before tax | 68 | 173 | 73 | 155 | (40) | 25 | 38 |
INR in Millions
Particular | FY 2018 | FY 2019 | FY 2020 |
Income from Operations | 2,664 | 3,227 | 2,578 |
Other Operating Income | 70 | 90 | 165 |
Total Income from Operations | 2,734 | 3,317 | 2,743 |
Operating Cost | 2,360 | 2,872 | 2,499 |
EBIDTA | 374 | 445 | 244 |
EBIT | 276 | 333 | 111 |
Finance costs | 94 | 105 | 126 |
Profit/(Loss) before exceptional item & tax | 182 | 228 | (15) |
Exceptional Item | (59) | - | - |
Profit/(Loss) before tax | 241 | 228.00 | (15) |
INR in Millions
Particular | FY 2018 | FY 2019 | FY 2020 | FY 2021 | |||
H1 | H2 | H1 | H2 | H1 | H2 | H1 | |
Property, plant and equipment including Capital work-in-progress | 936 | 977 | 1,079 | 1,072 | 1,114 | 1,122 | 1,079 |
Intangible assets including Intangible assets under development | 27 | 47 | 61 | 69 | 79 | 87 | 83 |
Other Non-Current Assets | 135 | 229 | 121 | 195 | 256 | 257 | 255 |
Current Assets | 1,870 | 1,721 | 1,941 | 1,912 | 1,927 | 1,763 | 1,806 |
Total assets | 2,968 | 2,974 | 3,202 | 3,248 | 3,376 | 3,229 | 3,223 |
---|---|---|---|---|---|---|---|
Equity | 1,223 | 1,360 | 1,407 | 1,512 | 1,500 | 1,518 | 1,544 |
Borrowings | 799 | 698 | 733 | 623 | 776 | 771 | 651 |
Other Non- Current Liabilities | - | - | - | - | 4 | 6 | 5 |
Current Liabilities | 946 | 916 | 1,062 | 1,113 | 1,096 | 934 | 1,023 |
Total equity and liabilities | 2,968 | 2,974 | 3,202 | 3,248 | 3,376 | 3,229 | 3,223 |
INR in Millions
Particular | FY 2018 | FY 2019 | FY 2020 |
Property, plant and equipment including Capital work-in-progress | 977 | 1,072 | 1,122 |
Intangible assets including Intangible assets under development | 47 | 69 | 87 |
Other Non-Current Assets | 229 | 195 | 257 |
Current Assets | 1,721 | 1,912 | 1,763 |
Total assets | 2,974 | 3,248 | 3,229 |
---|---|---|---|
Equity | 1,360 | 1,512 | 1,518 |
Borrowings | 698 | 623 | 771 |
Other Non- Current Liabilities | - | - | 6 |
Current Liabilities | 916 | 1,113 | 934 |
Total equity and liabilities | 2,974 | 3,248 | 3,229 |
INR in Millions
Current Presence
Target Markets